Dec. 9 at 12:27 PM
$CRDL $TRML Tourmaline vs. Cardiol comparison is almost unreal. Tourmaline was acquired for
$1.4B while still in Phase 2, based entirely on biomarker data: IL-6 down, CRP down, inflammation quieter. Strong numbers, yes — but no MRI data, no tissue reversal, no organ-level improvement. It’s systemic inflammation control, not disease repair.
CardiolRx, also post-Phase 2, trades at ~
$100M despite showing what biomarker drugs almost never prove: the heart structurally improving. ARCHER delivered LV-mass reduction, lower ECV/ICV, reduced edema, and healthier tissue signatures — objective signs that the myocardium is healing. That’s deeper biology, deeper relevance, and harder science than simple CRP drops.
Tourmaline was bought for lowering inflammation signals.
CardiolRx is showing the actual target organ recovering — and trades 14× cheaper.
One got
$1.4B for quieting blood markers.
The other gets
$100M for making hearts healthier.
At some point, the market fixes mispricing like this. DYOR.
